AXL‐Mediated Drug Resistance in ALK‐Rearranged NSCLC Enhanced by GAS6 From Macrophages and MMP11 Positive Fibroblasts
Cancer Science · 2025
DOI: 10.1111/cas.70006 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Science, 2025. Verfasst von Takahiro Utsumi und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Experimental Chemotherapy, Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, Tokyo, Japan. Hauptthemen laut MEDLINE: Drug Resistance, Neoplasm, Proto-Oncogene Proteins, Lung Neoplasms, Anaplastic Lymphoma Kinase. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Support for Pioneering Research Initiated by the Next Generation, Takeda Science Foundation, Chugai Foundation for Innovative Drug Discovery Science.
Abstract (Originalsprache)
Anaplastic lymphoma kinase (ALK) rearranged non‐small cell lung cancer (NSCLC) shows marked tumor shrinkage by ALK‐tyrosine kinase inhibitors (TKIs). However, tumors almost inevitably relapse owing to the development of acquired resistance. Resistance mechanisms include secondary ALK mutations and the activation of bypass pathways, such as cMET, cKIT, or EGFR, though some remain unknown. In this study, we analyzed alectinib‐resistant patient samples and identified a significant increase in AXL expression in the tumor, and a high level of GAS6, the ligand for AXL, in the pleural effusion. AXL‐overexpressing H3122 ALK‐rearranged NSCLC cells exhibited partial resistance to alectinib, which was enhanced by GAS6 supplementation but could be overcome by the ALK/AXL inhibitor gilteritinib. Moreover, GAS6‐overexpressing NIH3T3 cells and AXL‐expressing H3122 cells were subcutaneously injected into the left and right sides of nude mice simultaneously, followed by alectinib treatment. The supply of GAS6 from NIH3T3 may have accelerated tumor relapse under alectinib treatment. However, even without GAS6‐overexpressing NIH3T3, AXL‐overexpressing H3122 tumor relapsed within 1 month possibly due to increased host mouse Gas6 expression. Single‐cell RNA sequencing revealed that specific cancer‐associated fibroblasts (CAFs) and a subset of tumor‐associated macrophages (TAMs) are the primary sources of Gas6 in the tumor microenvironment (TME). During alectinib treatment, TAMs increased their infiltration into the TME, whereas CAFs altered their expression patterns, substantially upregulating Mmp11. These findings suggest that AXL expression in resistant cancer cells, combined with increased Gas6 production in the TME, contributes to enhanced ALK‐TKI resistance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Experimental Chemotherapy, Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, Tokyo, Japan.
- Department of Respiratory Medicine, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
- Department of Applied Chemistry, Faculty of Science and Technology, Keio University, Yokohama, Kanagawa, Japan.
- Department of Thoracic Medical Oncology, The Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.
- Department of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, The University of Tokyo, Tokyo, Japan.
ORCID-Profile: Makoto Nishio, Ryohei Katayama
Förderung
- Support for Pioneering Research Initiated by the Next Generation
- Takeda Science Foundation
- Chugai Foundation for Innovative Drug Discovery Science
- Nippon Foundation
- Japan Agency for Medical Research and Development
- Kobayashi Foundation for Cancer Research
- Mitsubishi Foundation
- Japan Society for the Promotion of Science
Zitieren
APA
Utsumi, T., Mizuta, H., Seto, Y., Uchibori, K., Nishio, M., Okamoto, I., & Katayama, R. (2025). AXL‐Mediated Drug Resistance in ALK‐Rearranged NSCLC Enhanced by GAS6 From Macrophages and MMP11 Positive Fibroblasts. Cancer Science. https://doi.org/10.1111/cas.70006
Vancouver
Utsumi T, Mizuta H, Seto Y, Uchibori K, Nishio M, Okamoto I, et al. AXL‐Mediated Drug Resistance in ALK‐Rearranged NSCLC Enhanced by GAS6 From Macrophages and MMP11 Positive Fibroblasts. Cancer Science. 2025. doi:10.1111/cas.70006
BibTeX
@article{Utsumi2025,
author = {Utsumi, Takahiro and Mizuta, Hayato and Seto, Yosuke and Uchibori, Ken and Nishio, Makoto and Okamoto, Isamu and Katayama, Ryohei},
title = {AXL‐Mediated Drug Resistance in ALK‐Rearranged NSCLC Enhanced by GAS6 From Macrophages and MMP11 Positive Fibroblasts},
journal = {Cancer Science},
year = {2025},
doi = {10.1111/cas.70006}
}
EUVIMED